{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T18:51:23Z","timestamp":1762023083834,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"am","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.neurol.2020.03.005","type":"journal-article","created":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T20:03:04Z","timestamp":1586376184000},"page":"500-504","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Do disease-modifying drugs (DMD) have a positive impact on the occurrence of secondary progressive multiple sclerosis? Comment"],"prefix":"10.1016","volume":"176","author":[{"given":"J.-C.","family":"Ouallet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.neurol.2020.03.005_bib0150","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJM200011163432001","article-title":"\u201cRelapses and progression of disability in multiple sclerosis\u201d","volume":"343","author":"Confavreux","year":"2000","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.neurol.2020.03.005_bib0155","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/ana.24018","article-title":"\u201cTreatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis\u201d","volume":"75","author":"Sormani","year":"2014","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.neurol.2020.03.005_bib0160","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s00415-015-7986-y","article-title":"\u201cOptimizing treatment success in multiple sclerosis\u201d","volume":"263","author":"Ziemssen","year":"2016","journal-title":"J Neurol"},{"issue":"5","key":"10.1016\/j.neurol.2020.03.005_bib0165","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1007\/s00415-015-7674-y","article-title":"\u201cThe outcome spectrum of multiple sclerosis: disability, mortality, and a cluster of predictors from onset\u201d","volume":"262","author":"Tedeholm","year":"2015","journal-title":"J Neurol"},{"issue":"2","key":"10.1016\/j.neurol.2020.03.005_bib0170","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0022-510X(02)00426-4","article-title":"\u201cPrognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis\u201d","volume":"206","author":"Vukusic","year":"2003","journal-title":"J Neurol Sci"},{"issue":"3","key":"10.1016\/j.neurol.2020.03.005_bib0175","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1177\/1352458507084264","article-title":"\u201cNatural history of secondary-progressive multiple sclerosis\u201d","volume":"14","author":"Tremlett","year":"2008","journal-title":"Mult Scler Houndmills"},{"issue":"1","key":"10.1016\/j.neurol.2020.03.005_bib0180","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/135245850100700110","article-title":"\u201cDisability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension\u201d","volume":"7","author":"Myhr","year":"2001","journal-title":"Mult Scler Houndmills"},{"issue":"9","key":"10.1016\/j.neurol.2020.03.005_bib0185","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/j.1468-1331.2008.02241.x","article-title":"\u201cNatural history of multiple sclerosis in a population-based cohort\u201d","volume":"15","author":"Debouverie","year":"2008","journal-title":"Eur J Neurol"},{"issue":"4","key":"10.1016\/j.neurol.2020.03.005_bib0190","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/ana.24747","article-title":"\u201cLong-term evolution of multiple sclerosis disability in the treatment era\u201d","volume":"80","author":"University of California","year":"2016","journal-title":"Ann Neurol"},{"issue":"11","key":"10.1016\/j.neurol.2020.03.005_bib0195","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1177\/1352458516681197","article-title":"\u201cClinical course of multiple sclerosis: a nationwide cohort study\u201d","volume":"23","author":"Manouchehrinia","year":"2017","journal-title":"Mult Scler Houndmills"},{"issue":"12","key":"10.1016\/j.neurol.2020.03.005_bib0200","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1177\/1352458510379246","article-title":"\u201cAssessing changes in relapse rates in multiple sclerosis\u201d","volume":"16","author":"Inusah","year":"2010","journal-title":"Mult Scler Houndmills"},{"issue":"12","key":"10.1016\/j.neurol.2020.03.005_bib0205","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1177\/1352458513481009","article-title":"\u201cExplaining temporal trends in annualised relapse rates in placebo groups of randomised controlled trials in relapsing multiple sclerosis: systematic review and meta-regression\u201d","volume":"19","author":"Steinvorth","year":"2013","journal-title":"Mult Scler Houndmills"},{"issue":"9","key":"10.1016\/j.neurol.2020.03.005_bib0210","doi-asserted-by":"crossref","first-page":"e0137052","DOI":"10.1371\/journal.pone.0137052","article-title":"\u201cChanging EDSS Progression in Placebo Cohorts in Relapsing MS: A Systematic Review and Meta-Regression\u201d","volume":"10","author":"R\u00f6ver","year":"2015","journal-title":"PloS One"},{"issue":"3","key":"10.1016\/j.neurol.2020.03.005_bib0215","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/nrneurol.2014.237","article-title":"\u201cCan we measure long-term treatment effects in multiple sclerosis?\u201d","volume":"11","author":"Sormani","year":"2015","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"10.1016\/j.neurol.2020.03.005_bib0220","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1177\/1352458514547407","article-title":"\u201cTen-year follow-up of the \u2018minimal MRI lesion\u2019 subgroup from the original CHAMPS Multiple Sclerosis Prevention Trial\u201d","volume":"21","author":"Simon","year":"2015","journal-title":"Mult Scler Houndmills"},{"key":"10.1016\/j.neurol.2020.03.005_bib0225","first-page":"CD012200","article-title":"\u201cTreatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis\u201d","volume":"4","author":"Filippini","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.neurol.2020.03.005_bib0230","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00415-018-8752-8","article-title":"\u201cShort- and long-term clinical outcomes of use of beta-interferon or glatiramer acetate for people with clinically isolated syndrome: a systematic review of randomised controlled trials and network meta-analysis\u201d","volume":"265","author":"Armoiry","year":"2018","journal-title":"J Neurol"},{"issue":"10","key":"10.1016\/j.neurol.2020.03.005_bib0235","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1212\/WNL.0000000000003078","article-title":"\u201cThe 11-year long-term follow-up study from the randomized BENEFIT CIS trial\u201d","volume":"87","author":"Kappos","year":"2016","journal-title":"Neurology"},{"issue":"Suppl 1","key":"10.1016\/j.neurol.2020.03.005_bib0240","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.clineuro.2013.09.024","article-title":"\u201cInterferon-beta and disability progression in relapsing-remitting multiple sclerosis\u201d","volume":"115","author":"Drulovic","year":"2013","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.neurol.2020.03.005_bib0245","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.msard.2016.01.007","article-title":"\u201cLong-term impact of interferon or Glatiramer acetate in multiple sclerosis: a systematic review and meta-analysis\u201d","volume":"6","author":"Signori","year":"2016","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurol.2020.03.005_bib0250","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1136\/jnnp-2018-318360","article-title":"\u201cAssessing the long-term effectiveness of interferon-beta and glatiramer acetate in multiple sclerosis: final 10-year results from the UK multiple sclerosis risk-sharing scheme\u201d","volume":"90","author":"Palace","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"13","key":"10.1016\/j.neurol.2020.03.005_bib0255","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1177\/1352458512445941","article-title":"\u201cImmunomodulatory therapies delay disease progression in multiple sclerosis\u201d","volume":"22","author":"Bergamaschi","year":"2016","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"issue":"4","key":"10.1016\/j.neurol.2020.03.005_bib0260","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1474-4422(17)30007-8","article-title":"\u201cTreatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study\u201d","volume":"16","author":"Kalincik","year":"2017","journal-title":"Lancet Neurol"},{"year":"2017","series-title":"The effect of disease-modifying treatments on conversion to secondary progressive multiple sclerosis [Online]","author":"Brown","key":"10.1016\/j.neurol.2020.03.005_bib0265"},{"issue":"13","key":"10.1016\/j.neurol.2020.03.005_bib0270","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1177\/1352458516687402","article-title":"\u201cAssessing long-term prognosis improvement as a consequence of treatment pattern changes in MS\u201d","volume":"23","author":"Capra","year":"2017","journal-title":"Mult Scler Houndmills"},{"issue":"10","key":"10.1016\/j.neurol.2020.03.005_bib0275","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1001\/jamaneurol.2015.1788","article-title":"\u201cEffect of smoking cessation on multiple sclerosis prognosis\u201d","volume":"72","author":"Ramanujam","year":"2015","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.neurol.2020.03.005_bib0280","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1212\/WNL.0000000000000541","article-title":"\u201cLong-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study\u201d","volume":"83","author":"O\u2019Connor","year":"2014","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.neurol.2020.03.005_bib0285","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"\u201cAn introduction to propensity score methods for reducing the effects of confounding in observational studies\u201d","volume":"46","author":"Austin","year":"2011","journal-title":"Multivar Behav Res"},{"issue":"Pt 9","key":"10.1016\/j.neurol.2020.03.005_bib0290","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1093\/brain\/aww173","article-title":"\u201cDefining secondary progressive multiple sclerosis\u201d","volume":"139","author":"Lorscheider","year":"2016","journal-title":"Brain J Neurol"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378720304951?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378720304951?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T05:40:42Z","timestamp":1758519642000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378720304951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0035378720304951"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2020.03.005","relation":{},"ISSN":["0035-3787"],"issn-type":[{"type":"print","value":"0035-3787"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Do disease-modifying drugs (DMD) have a positive impact on the occurrence of secondary progressive multiple sclerosis? Comment","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2020.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2020.03.004","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2020.03.003","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}